New lens implant helps presbyopia patients ditch reading glasses

NCT ID NCT03499821

Completed Symptom relief Sponsor: Staar Surgical Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special lens implant (EVO+ Visian ICL) to improve near vision in 41 adults with presbyopia, an age-related condition that makes it hard to see up close. The lens is placed behind the iris and in front of the eye's natural lens. Six months after surgery, most eyes could see 20/40 or better at 40 cm without glasses. The results suggest this implant may be a helpful option for people who need reading glasses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EVO+ Visian ICL with Aspheric (EDOF) Optic (a lens implant)
What this could lead to: If successful, this lens could help people with presbyopia see up close without reading glasses.
What could go wrong: This is a small, completed study with only 41 participants. Long-term safety and effectiveness are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRESBYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRESBYOPIA

Contacts and locations

Locations

Clínica Oftalmológica Gasteiz

Vitoria-Gasteiz, 01005, Spain
IMO Instituto de Microcirugía Ocular

Barcelona, 08035, Spain
Innova Ocular Begitek

San Sebastián, 20012, Spain
Instituto Oftalmológico Fernández-Vega

Oviedo, Principality of Asturias, 33012, Spain
Mediopolis

Antwerp, B-2610, Belgium
Qvision-Hospital Vithas Virgen del Mar

Almería, 04120, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.